Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
IBRN ETF — iShares Neuroscience and Healthcare ETF
iShares Neuroscience and Healthcare ETF (IBRN)
Updated October 16, 2026.
Verdict as of October 16, 2026
IBRN's distribution is rated unproven by the Dividend Vision Distribution Safety Score™ (50/100, low confidence). It pays its distribution rate is 0.99%. The latest total cash payment per current share, $0.32 with an ex-date of December 16, 2025, was 216.8% higher than the previous $0.101. These payments are unclassified; this does not establish a base-dividend change.
Sources: iShares page for IBRN, Section 19a-1 notices, scoring methodology.
IBRN is an ETF that tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index. its distribution rate is 0.99%, its trailing-12-month yield is 1.07%, its expense ratio is 0.47%. Dividend Vision Distribution Safety Score™ is 50/100 (Unproven). Total return is 23.7% over the past 4.1 years, 75.5 points behind SPY at 99.2%.
iShares Neuroscience and Healthcare ETF is an ETF that tracks an index of global companies engaged in research and treatment of neurological disorders, holding at least eighty percent of its assets in index component securities. The fund carries a modest expense ratio and a low current distribution rate, with distributions on an irregular schedule; the latest payout was special and may not recur regularly. This fund appeals to investors seeking exposure to the neuroscience and healthcare innovation sector.
IBRN dividend yield and income
Price as of 2026-10-16.
Trailing-12-month yield (1.07%) is the last year of cash distributions by ex-date divided by the current price. The dividend amount is $0.32. The ex-dividend date is 12/16/2025. The payment date is 12/19/2025.
| Ex-date | Amount | Change from previous payment |
|---|---|---|
| 2025-12-16 | $0.32 | 216.8% Unclassified cash |
| 2024-12-17 | $0.101 | 1583.3% Unclassified cash |
| 2023-12-20 | $0.006 | -25.0% Unclassified cash |
| 2023-06-07 | $0.008 | — |
| 2023 total | $0.014 | — |
| 2024 total | $0.101 | 621.4% |
| 2025 total | $0.32 | 216.8% |
IBRN dividend growth
Trailing-12-month distributions versus the preceding 12 months changed +216.8%. The 1Y row below uses this same adjacent TTM cash-window comparison.
| Window | Change |
|---|---|
| 1Y | +216.8% |
IBRN holdings and sector exposure
Holdings are not available for this snapshot.
IBRN performance versus SPY
Price and return data through 2026-10-16.
Total return is 23.7% over the past 4.1 years, 75.5 points behind SPY at 99.2%. Over the past year its total return — price change plus distributions reinvested — is 4.9%. Its deepest 1-year drawdown was 26.3%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -16.8% | — |
| 3M | -19.8% | — |
| 6M | -13.8% | — |
| YTD | -7.3% | — |
| 1Y | 4.9% | — |
| 2Y CAGR | — | 5.40% |
| 3Y CAGR | — | 13.40% |
| Since inception (4.1 years) | 23.7% | 5.30% |
IBRN key facts
- Distribution Safety Score™
- 50 · Unproven
- Issuer
- iShares
- Asset type
- ETF
- Asset class
- Equity
- Inception date
- 08/24/2022
- Expense ratio
- 0.47%
- Distribution rate
- 0.99%
- Trailing yield
- 1.07%
- Last close
- $29.97 (as of 2026-10-16)
- AUM
- $6,357,820
- Average volume
- 494.0
- Dividend
- $0.32
- Ex-dividend date
- 12/16/2025
- Payment date
- 12/19/2025
- Beta
- 0.88
How Dividend Vision calculates yield and returns
Distribution rate (0.99%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (1.07%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: iShares or company page; Fact sheet; Index: NYSE FactSet Global Neuro Biopharma and MedTech Index; prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
IBRN risks and drawbacks
IBRN's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 26.3%.
Who may consider IBRN — and who may not
It is a weaker fit for investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on IBRN
Frequently asked questions
What index does IBRN track?
IBRN tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index.
What is IBRN's expense ratio?
IBRN's expense ratio is 0.47%.
How has IBRN's dividend grown?
Trailing-12-month distributions versus the preceding 12 months changed +216.8%. That is the same adjacent TTM cash-window comparison used in the dividend-history table.
When does IBRN pay a dividend?
The dividend amount is $0.32. The ex-dividend date is 12/16/2025. The payment date is 12/19/2025.
How has IBRN performed?
Total return is 23.7% over the past 4.1 years, 75.5 points behind SPY at 99.2%. Over the past year its total return — price change plus distributions reinvested — is 4.9%. Its deepest 1-year drawdown was 26.3%.
Is IBRN a good investment?
IBRN's Dividend Vision Distribution Safety Score is 50 (Unproven). That is a risk signal, not investment advice. Its distribution rate is 0.99% (calculation basis unavailable). Compare peers below rather than treating any single figure as a buy or sell.
More securities from iShares.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.